Icatibant Teva (Icatibant Acetate)

Icatibant, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as a 30 mg/0.3 mL solution for injection for subcutaneous use. It treats hereditary angioedema caused by C1‑inhibitor deficiency in patients who need rapid relief of acute swelling episodes.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is indicated for the treatment of hereditary angioedema, a bradykinin‑mediated angioedema disorder. - Hereditary angioedema (C1‑inhibitor deficiency) – acute attacks: Provides rapid reduction of swelling and associated pain. - Hereditary angioedema (C1‑inhibitor deficiency) – adult patients: Enables on‑demand subcutaneous self‑administration. - Hereditary angioedema (C1‑inhibitor deficiency) – type I and II: Effective in both subtypes for acute symptom control.

Icatibant may cause a range of adverse reactions, most of which are related to its subcutaneous administration and pharmacologic activity.

Common Side Effects: - Injection site pain: Discomfort at the site of subcutaneous injection. - Redness or erythema: Localized skin reddening. - Swelling at injection site: Mild to moderate edema. - Nausea: Transient gastrointestinal upset. - Headache: Mild to moderate intensity.

Serious or Rare Side Effects: - Anaphylaxis: Severe allergic reaction requiring immediate medical attention. - Hypotension: Significant drop in blood pressure. - Laryngeal edema: Swelling of the throat that may compromise airway. - Severe urticaria: Widespread hives. - Angioedema unrelated to HAE: Unexpected swelling in other body parts.

When using Icatibant, certain safety considerations should be observed. - Renal impairment: Use with caution and monitor renal function. - Hepatic impairment: Adjust therapy if liver function is compromised. - Pregnancy: Safety not established; avoid unless benefit outweighs risk. - Breastfeeding: Unknown safety; consider potential risks. - Concomitant ACE inhibitors: May increase bradykinin levels; monitor closely. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: May potentiate bradykinin‑mediated angioedema. - Angiotensin receptor blockers: Similar risk of enhanced bradykinin effects. - Nitrates: Additive vasodilatory effect leading to hypotension.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: May increase frequency of HAE attacks. - Diuretics: Can affect fluid balance and blood pressure.